DiscoverCME in Minutes: Education in Primary CareStephanie A. Christenson, MD, MAS - ​Targeting Eosinophils for Fewer Exacerbations:​ The Future of Biologic Treatments in COPD Management
Stephanie A. Christenson, MD, MAS - ​Targeting Eosinophils for Fewer Exacerbations:​ The Future of Biologic Treatments in COPD Management

Stephanie A. Christenson, MD, MAS - ​Targeting Eosinophils for Fewer Exacerbations:​ The Future of Biologic Treatments in COPD Management

Update: 2024-09-20
Share

Description

Please visit answersincme.com/PES860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary disease discusses the implications of the latest evidence on biologic therapies targeting type 2 inflammation for the treatment of chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD); Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations; Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available. This activity is intended for US healthcare professionals only.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Stephanie A. Christenson, MD, MAS - ​Targeting Eosinophils for Fewer Exacerbations:​ The Future of Biologic Treatments in COPD Management

Stephanie A. Christenson, MD, MAS - ​Targeting Eosinophils for Fewer Exacerbations:​ The Future of Biologic Treatments in COPD Management

Answers in CME